Fig. 5.

Therapeutic efficacy of TOFU mRNA vaccines in combination with ACT. a Timeline for therapy administration for the TOFU vaccine plus ACT combination approach following host conditioning with 9 Gy TBI and HSCs. b Kluc tumor growth measurement using in vivo luminescence imaging at day 32 after the tumor implantation (n = 5 per group). Statistical analysis was done using one-way ANOVA and Tukey’s multiple comparisons; p < 0.05 is *, p < 0.01 is **, and p < 0.001 is ***. c Survival curve of Kluc tumor-bearing mice treated with Kluc TOFU-ACT and control treatments (n = 7 to 9). d Survival curve of GL261 tumor-bearing mice treated with GL261 TOFU-ACT and control treatments (n = 7 to 9). Statistical analysis was performed using the log-rank (Mantel-Cox) test with significance at p < 0.05. e Uniform Manifold Approximation and Projection (UMAP) of 1000 CD45 − ve single cells from the TOFU-ACT and control groups which were resolved into 8 clusters. The cell type and the percentage of cells are labeled across the respective population